Compare MBI & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBI | ESPR |
|---|---|---|
| Founded | 1973 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 381.2M | 898.5M |
| IPO Year | 1987 | 2013 |
| Metric | MBI | ESPR |
|---|---|---|
| Price | $7.10 | $3.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $8.50 | $6.67 |
| AVG Volume (30 Days) | 334.9K | ★ 6.5M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $93,000,000.00 | ★ $303,802,000.00 |
| Revenue This Year | N/A | $25.45 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 285.71 | 2.83 |
| 52 Week Low | $3.86 | $0.69 |
| 52 Week High | $8.26 | $4.13 |
| Indicator | MBI | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 42.26 | 59.47 |
| Support Level | $6.93 | $3.63 |
| Resistance Level | $7.85 | $4.13 |
| Average True Range (ATR) | 0.27 | 0.20 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 18.48 | 64.00 |
MBIA Inc provides financial guaranty insurance for municipal bonds and asset-backed securities in the United States and internationally. It offers an unconditional guarantee to repay the principal and interest on these securities if the issuer defaults. MBIA insures bonds sold in the primary and secondary markets, as well as those held in unit investment trusts and mutual funds. It operates in three segments: the United States Public Finance Insurance, which derives maximum revenue, Corporate, and International & Structured Finance Insurance. U.S. public finance insurance portfolio is managed through the National Public Finance Guarantee Corporation. International & structured finance insurance business is managed through MBIA Insurance Corporation and its subsidiary.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.